Soleno Therapeutics (SLNO) EBIT: 2013-2024
Historic EBIT for Soleno Therapeutics (SLNO) over the last 9 years, with Dec 2024 value amounting to -$187.7 million.
- Soleno Therapeutics' EBIT fell 183.62% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 17.49%. This contributed to the annual value of -$187.7 million for FY2024, which is 353.49% down from last year.
- Soleno Therapeutics' EBIT amounted to -$187.7 million in FY2024, which was down 353.49% from -$41.4 million recorded in FY2023.
- Over the past 5 years, Soleno Therapeutics' EBIT peaked at -$24.4 million during FY2022, and registered a low of -$187.7 million during FY2024.
- Moreover, its 3-year median value for EBIT was -$41.4 million (2023), whereas its average is -$84.5 million.
- Data for Soleno Therapeutics' EBIT shows a maximum YoY slumped of 353.49% (in 2024) over the last 5 years.
- Yearly analysis of 3 years shows Soleno Therapeutics' EBIT stood at -$24.4 million in 2022, then tumbled by 69.63% to -$41.4 million in 2023, then slumped by 353.49% to -$187.7 million in 2024.